Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

Accsys Technologies PLC (LON:AXS – Get Free Report) insider Louis Eperjesi bought 21,000 shares of the company’s stock in a ...

On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...

Axsome Therapeutics (NASDAQ:AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with ...

Shares of AXIS Capital Holdings Limited (NYSE:AXS – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday after TD Cowen raised their price target on the stock from $118.00 to ...

The AXS Knowledge Leaders ETF has a unique investment approach, focusing on innovative global companies with strong R&D and ...

Axsome Therapeutics (AXSM) announced that AXS-12 achieved the primary endpoint in the ENCORE Phase 3 trial, demonstrating a statistically ...

Axis Capital (AXS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.